MedinCell’s partner AIC registers trial for drug for total knee replacement pain
A partner of MedinCell, Arthritis Innovation Corporation (AIC), has registered a phase 3 trial to look into an alternative drug to deal with pain after total knee replacement (TKR).
Arthritis Innovation Corporation conducts and finances all development activities of the drug F14, or mdc-CWM, being trialed.
It was registered with the safety and efficacy study on the public trials registry, clinicaltrials.gov, and enrollment of the first patients is expected this month. It will be carried out in the U.S. and was designed in consultation with the Food and Drug Administration (FDA).
F14 which is 625 mg of sustained release celecoxib, a formulation of non-steroidal, anti-inflammatory drug (NSAID) is administered concurrent with multimodal analgesia in patients undergoing total knee replacement (TKR) surgery compared to multimodal analgesia alone.
F14 is a sustained-release formulation of the non-steroidal anti-inflammatory drug (NSAID), celecoxib, designed to reduce pain and inflammation and enhance recovery after TKR. It is administered into the intra-articular space at the end of TKR surgery and may provide pain relief over several weeks post-surgery.
Wayne Marshall, CEO at AIC said: “TKR is one of the most invasive and painful surgeries. F14 was designed and developed to reduce surgical pain and swelling, accelerate functional improvement and potentially reduce opioid consumption for TKR patients.
Click here to read the original article.